NZ619899A - Tissue targeted antigenic activation of the immune response to treat cancers - Google Patents
Tissue targeted antigenic activation of the immune response to treat cancersInfo
- Publication number
- NZ619899A NZ619899A NZ619899A NZ61989907A NZ619899A NZ 619899 A NZ619899 A NZ 619899A NZ 619899 A NZ619899 A NZ 619899A NZ 61989907 A NZ61989907 A NZ 61989907A NZ 619899 A NZ619899 A NZ 619899A
- Authority
- NZ
- New Zealand
- Prior art keywords
- human patient
- tissue
- specific
- specific organ
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 230000000890 antigenic effect Effects 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title 1
- 210000000056 organ Anatomy 0.000 abstract 6
- 210000001519 tissue Anatomy 0.000 abstract 6
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000002458 infectious effect Effects 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 210000004100 adrenal gland Anatomy 0.000 abstract 1
- 210000000436 anus Anatomy 0.000 abstract 1
- 210000003445 biliary tract Anatomy 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 210000002640 perineum Anatomy 0.000 abstract 1
- 210000004303 peritoneum Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 abstract 1
- 210000000626 ureter Anatomy 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is the use of a non-infectious antigenic composition in the manufacture of a medicament for eliciting an immune response in a human patient suffering from cancer to treat the cancer situated in a specific organ or specific tissue of the human patient, or to prevent or ameliorate the metastasis of the cancer from a primary site in the human patient to a secondary site in the specific organ or specific tissue of the human patient, wherein: - the non-infectious antigenic composition comprises at least one attenuated bacteria of a species or strain that is pathogenic in the specific organ or tissue of the human patient; - the non-infectious antigenic composition does not produce infection in the specific organ or specific tissue of the human patient; and wherein, - the attenuated bacteria is an Escherichia coli and the specific organ or tissue is selected from the group consisting of: intra-abdominal lymph nodes; haematological tissues or organs; bone; brain; eye or orbit; small bowel; colon; rectum; anus; perineum; liver; gall bladder; biliary tract; pancreas; spleen; adrenal gland; kidney; ureter; bladder; peritoneum; prostate; testicle; ovary; adnexa; uterus; and vagina.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ715882A NZ715882A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/553,972 US20070104733A1 (en) | 2004-06-07 | 2006-10-27 | Tissue targeted antigenic activation of the immune response to cancers |
| CA2571805A CA2571805C (en) | 2006-10-27 | 2006-12-20 | Tissue targeted antigenic activation of the immune response to cancers |
| NZ601232A NZ601232A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ619899A true NZ619899A (en) | 2016-08-26 |
Family
ID=39324077
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ619899A NZ619899A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ601232A NZ601232A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ715882A NZ715882A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ576590A NZ576590A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601232A NZ601232A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ715882A NZ715882A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ576590A NZ576590A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Country Status (2)
| Country | Link |
|---|---|
| NZ (4) | NZ619899A (en) |
| WO (1) | WO2008049231A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| DK2598165T3 (en) * | 2010-07-26 | 2017-10-16 | Qu Biologics Inc | IMMUNOGENIC ANTI-INFLAMMATORY COMPOSITIONS |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| CA2813080A1 (en) * | 2010-10-04 | 2012-04-12 | British Columbia Cancer Agency Branch | Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer |
| CN106456740B (en) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | Antimicrobial immunomodulation |
| JP2019514939A (en) | 2016-04-26 | 2019-06-06 | クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． | Therapeutic induction of innate immune response in target tissues |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001233076A1 (en) * | 2000-02-01 | 2001-08-14 | Michael A. O'donnell | Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen |
| NZ533422A (en) * | 2001-12-11 | 2008-03-28 | Pasteur Institut | Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
| NZ581806A (en) * | 2004-06-07 | 2011-10-28 | Qu Biolog Inc | Bacterial compositions for the treatment of cancer |
-
2007
- 2007-10-25 WO PCT/CA2007/001915 patent/WO2008049231A1/en active Application Filing
- 2007-10-25 NZ NZ619899A patent/NZ619899A/en not_active IP Right Cessation
- 2007-10-25 NZ NZ601232A patent/NZ601232A/en not_active IP Right Cessation
- 2007-10-25 NZ NZ715882A patent/NZ715882A/en unknown
- 2007-10-25 NZ NZ576590A patent/NZ576590A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ715882A (en) | 2017-07-28 |
| WO2008049231A1 (en) | 2008-05-02 |
| NZ576590A (en) | 2012-08-31 |
| NZ601232A (en) | 2014-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ619899A (en) | Tissue targeted antigenic activation of the immune response to treat cancers | |
| CY1124556T1 (en) | IMPLANTABLE DEVICE FOR INTERNAL CONTROL OF URINE | |
| BR0108178B1 (en) | apparatus for the treatment of anal incontinence with wireless power supply. | |
| WO2008088645A3 (en) | Trans urinary bladder access device and method | |
| Doughty | History of ostomy surgery | |
| Chen et al. | The morbidity of defunctioning stomata | |
| Highton et al. | Necrotising fasciitis of the thigh secondary to a perforated rectal cancer | |
| Altomare et al. | Graciloplasty for recurrent recto-neovaginal fistula in a male-to-female transsexual | |
| NZ713972A (en) | Use of a neuregulin to treat peripheral nerve injury | |
| Jermini et al. | Noninvasive anesthesia, analgesia and radiation-free extracorporeal shock wave lithotripsy for stones in the most distal ureter: experience with 165 patients | |
| Fixot et al. | Abdominoperineal pull-through resection with delayed coloanal anastomosis as treatment option for complex recto-urinary fistulas | |
| Carballo et al. | Total pelvic exenteration for the treatment of advanced primary or recurrent pelvic neoplasia | |
| CN204723381U (en) | Smoked therapeutic apparatus in a kind of Urology Surgery | |
| McLemore et al. | Transanal endoscopic surgical proctectomy for proctitis case series report: diversion, radiation, ulcerative colitis, and Crohn’s disease | |
| Chen | AB042. Rehabilitation period care for patients with urinary ostomy | |
| Coulson et al. | Managing a wet colostomy | |
| Eke | Urogenital tract trauma in Port Harcourt | |
| RU2231376C1 (en) | Method for treating the cases of chronic prostatitis combined with benign prostate hyperplasia | |
| RU2408399C1 (en) | Method of treating benign prostatic hyperplasia | |
| Romano et al. | From mininvasive to maxinvasive surgery in colorectal cancer: modern evolution of oncologic specialized units | |
| Singh et al. | Delayed post‐traumatic prostatic‐urethrorectal fistula: Transperineal rectal sparing repair–Point of technique | |
| Goonewardene et al. | Dysuria | |
| CN105749416A (en) | Conduit device | |
| Kozlow et al. | Female urethral reconstruction using a tubed rectus abdominis myocutaneous flap | |
| Piazza et al. | A technique of transrectal ultrasound guided transperineal percutaneous drainage of pelvic abscess after radical cystectomy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 25 OCT 2017 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20170323 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2018 BY CPA GLOBAL Effective date: 20170929 |
|
| LAPS | Patent lapsed |